Moreover, systemically administered Tat-Gap19 has been shown to decrease seizure activity in animal epilepsy models (86) and to prevent neuronal cell loss in Parkinson’s disease (87), indicating it is biologically active in the brain. Here, TAT is linked to epilepsy.